Skip to main content
PMC home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1993 Jul 15;90(14):6889–6893. doi: 10.1073/pnas.90.14.6889

Diazepam dependence prevented by glutamate antagonists.

K G Steppuhn 1, L Turski 1
PMCID: PMC47038  PMID: 8341715

Abstract

Long-term treatment leads to tolerance to and dependence on benzodiazepines. Abrupt termination of benzodiazepine administration triggers the expression of signs of dependence. Mice withdrawn from chronic treatment with diazepam showed a time-related evolution of anxiety, muscle rigidity, and seizures between days 4 and 21 after treatment discontinuation. A period between withdrawal days 1 and 3 was symptom-free. Surprisingly, during this "silent phase" the susceptibility of mice to alpha-amino-3-hydroxy-5-tert-butyl-4-isoxazolepropionate (ATPA) and kainate seizures and the magnitude of monosynaptic reflexes mediated by non-N-methyl-D-aspartate (NMDA) mechanisms were enhanced. In apparent contrast, the "active phase", between withdrawal days 4 and 21, was characterized by increased susceptibility to NMDA seizures and enhanced magnitude of polysynaptic reflexes, which are NMDA dependent. Treatment of mice with alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) antagonists 1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine (GYKI 52466) or 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline but not with the NMDA antagonist 3-[(+/-)-2-carboxypiperazin-4-yl]-propyl-1-phosphonate (CPP) during the silent phase prevented signs of dependence. In contrast, treatment with CPP but not with GYKI 52466 during the active phase prevented the symptoms. The development of tolerance to and dependence on diazepam was prevented by concurrent treatment of mice with CPP but was not prevented by GYKI 52466. These data indicate that NMDA-dependent mechanisms contribute to the development of tolerance to diazepam and to the expression of signs of dependence in mice after termination of long-term treatment with diazepam. Nevertheless, the non-NMDA-mediated silent phase is essential for triggering the symptoms. Therefore, AMPA antagonists may offer a therapeutic approach for preventing dependence on benzodiazepines that is an alternative to NMDA antagonism.

Full text

PDF
6893

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brady J. V. Animal models for assessing drugs of abuse. Neurosci Biobehav Rev. 1991 Spring;15(1):35–43. doi: 10.1016/s0149-7634(05)80089-2. [DOI] [PubMed] [Google Scholar]
  2. Collier H. O. Cellular site of opiate dependence. Nature. 1980 Feb 14;283(5748):625–629. doi: 10.1038/283625a0. [DOI] [PubMed] [Google Scholar]
  3. Donevan S. D., Rogawski M. A. GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses. Neuron. 1993 Jan;10(1):51–59. doi: 10.1016/0896-6273(93)90241-i. [DOI] [PubMed] [Google Scholar]
  4. File S. E. The history of benzodiazepine dependence: a review of animal studies. Neurosci Biobehav Rev. 1990 Summer;14(2):135–146. doi: 10.1016/s0149-7634(05)80214-3. [DOI] [PubMed] [Google Scholar]
  5. HOLLISTER L. E., MOTZENBECKER F. P., DEGAN R. O. Withdrawal reactions from chlordiazepoxide ("Librium"). Psychopharmacologia. 1961 Feb 20;2:63–68. doi: 10.1007/BF00429621. [DOI] [PubMed] [Google Scholar]
  6. Koob G. F., Bloom F. E. Cellular and molecular mechanisms of drug dependence. Science. 1988 Nov 4;242(4879):715–723. doi: 10.1126/science.2903550. [DOI] [PubMed] [Google Scholar]
  7. Lukas S. E., Griffiths R. R. Precipitated withdrawal by a benzodiazepine receptor antagonist (Ro 15-1788) after 7 days of diazepam. Science. 1982 Sep 17;217(4565):1161–1163. doi: 10.1126/science.6287579. [DOI] [PubMed] [Google Scholar]
  8. Roy-Byrne P. P., Hommer D. Benzodiazepine withdrawal: overview and implications for the treatment of anxiety. Am J Med. 1988 Jun;84(6):1041–1052. doi: 10.1016/0002-9343(88)90309-9. [DOI] [PubMed] [Google Scholar]
  9. Sellers E. M. Alcohol, barbiturate and benzodiazepine withdrawal syndromes: clinical management. CMAJ. 1988 Jul 15;139(2):113–120. [PMC free article] [PubMed] [Google Scholar]
  10. Steppuhn K. G., Turski L. Modulation of the seizure threshold for excitatory amino acids in mice by antiepileptic drugs and chemoconvulsants. J Pharmacol Exp Ther. 1993 Jun;265(3):1063–1070. [PubMed] [Google Scholar]
  11. Trujillo K. A., Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science. 1991 Jan 4;251(4989):85–87. doi: 10.1126/science.1824728. [DOI] [PubMed] [Google Scholar]
  12. Turski L., Jacobsen P., Honoré T., Stephens D. N. Relief of experimental spasticity and anxiolytic/anticonvulsant actions of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline. J Pharmacol Exp Ther. 1992 Feb;260(2):742–747. [PubMed] [Google Scholar]
  13. Woods J. H., Katz J. L., Winger G. Abuse liability of benzodiazepines. Pharmacol Rev. 1987 Dec;39(4):251–413. [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES